drugset
drugset / Trial / NCT03604445

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

NCT03604445 ↗

Phase 1 Terminated 37 enrolled Boehringer Ingelheim
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is open to adults with different types of advanced cancer (solid tumours). This study is open to people in whom previous treatments were not successful. The purpose of this study is to find out the highest dose of BI 905677 the participants can tolerate. BI 905677 is a type of an antibody that is being developed to treat cancer. One dose of BI 905677 is given to the participants every 2 or 3 weeks as infusion into a vein. In this study, BI 905677 is given to humans for the first time. The participants visit the study site at least once a week so that the doctors can check their general health. The participants are in the study for as long as they benefit from and can tolerate treatment.

Timeline

Start
2018-08-08
Primary completion
2022-07-27
Completion
2022-07-27

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 905677 Unknown 0.05 mg/kg Intravenous
Subject BI 905677 Unknown 0.1 mg/kg Intravenous
Subject BI 905677 Unknown 0.2 mg/kg Intravenous
Subject BI 905677 Unknown 0.4 mg/kg Intravenous
Subject BI 905677 Unknown 0.8 mg/kg Intravenous
Subject BI 905677 Unknown 1.6 mg/kg Intravenous
Subject BI 905677 Unknown 2.4 mg/kg Intravenous
Subject BI 905677 Unknown 2.8 mg/kg Intravenous
Subject BI 905677 Unknown 3.6 mg/kg Intravenous

Indications

neoplasm